Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers
SYDNEY, AU, Aug 20, 2020 - (ACN Newswire) - Triple therapy specialist Professor Thomas Borody, famous for curing peptic ulcers using a triple antibiotic therapy and saving millions of lives, has released the Triple Therapy Protocol for COVID-19 to Australian GPs, who can legally prescribe it to their COVID-19 positive patients, or prescribe it as a preventative medication.
| The Centre for Digestive Disease (CDD) Medical Director Professor Thomas Borody |
Borody says this could be the fastest and safest way to end the pandemic in Australia within 6-8 weeks.
Professor Thomas Borody MB, BS, BSc(Med), MD, PhD, DSc, FRACP, FACP, FACG, AGAF, FRS(N) said: "The three medications are on chemist shelves right now. GPs can email GP@CDD.com.au to obtain the dosing protocol and COVID-19 treatment information for their patients.
"GPs can legally prescribe the therapy today as an "off label" treatment according to Australian Guidelines - a standard practice in medicine. In fact more than 60% of prescriptions in Australia are "off-label". It's not a new concept. It's happening every day to manage diseases and save lives."
Professor Borody continued: "We have a therapy that can fight COVID-19. The medications have been around for 50 years, they are cheap, FDA and TGA approved and have an outstanding safety profile. Why are we just waiting around for a vaccine? To save lives we should be using whatever is safe and available right now. We could lead the world in this fight.
"Australia has some of the best medical and science people in the world - indeed the Ivermectin connection was first discovered by Dr Kylie Wagstaff's team at Monash University in April. How long do we need to wait before Australian politicians get behind Australian medical science and use 'war room' tactics with safe and approved medications."
Professor Borody, an internationally regarded physician with 4 FDA approved drugs on the US and Australian markets, is famous for developing the triple therapy that cured peptic ulcers, saving more than 18,000 lives just in Australia and millions internationally. [See Professor Borody's published research at ORCID: http://orcid.org/0000-0002-0519-4698]
"No trial has shown Ivermectin-based therapy to be ineffective. In-fact, international data reports an almost 100% cure rate and a symptom improvement within 4-6 days. We should share Australian findings from this triple therapy with the world," said Professor Borody.
"An Ivermectin tablet can cost as little as $2 - which could make it by far the cheapest, safest, and fastest cure for Australians and the Australian economy. This needs to be available for aged care facilities and frontline health workers today.
"We have written the Federal Health Minister Greg Hunt and Victorian Premier Daniel Andrews for an urgent medical briefing to bypass the raft of 'advisors' who need to know TGA-approved medicines do not require animal studies and prolonged clinical trials already done to approve them in the first place.
"The Government could end the pandemic by openly encouraging GPs to prescribe these TGA approved medications. Those who test positive, are identified in contact tracing, as well as those in high-risk groups like the elderly and healthcare workers, can then access the therapy quickly," said Professor Borody.
Ivermectin was discovered in the 1970s and is on the World Health Organization (WHO) list of essential medicines. "There is mounting worldwide clinical literature pointing to a 100% cure rate using Ivermectin Triple Therapy," he said.
There are currently 28 COVID-19 Ivermectin treatment studies running globally. Research papers include:
WHO: Mass treatment with ivermectin: an underutilized public health strategy https://www.who.int/bulletin/volumes/82/8/editorial30804html/en/
ResearchSquare: A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients https://www.researchsquare.com/article/rs-38896/v1
MedRxiv: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1
Journal of Antibiotics: Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen https://www.nature.com/articles/s41429-020-0336-z
ResearchGate: A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline https://www.researchgate.net/publication/343305357 _A_Case_Series_of_100_COVID-19_Positive_Patients_Treated_with_Combination_of_Ivermectin_and_Doxycycline
Journal of Bangladesh College of Physicians and Surgeons: A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline https://www.banglajol.info/index.php/JBCPS/article/view/47512
Journal of Bangladesh College of Physicians and Surgeons: Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients https://www.banglajol.info/index.php/JBCPS/article/view/47514
MedRxiv: ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2
ChemRxiv: Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent https://chemrxiv.org/articles/preprint/12782258 Has_Ivermectin_Virus-Directed_Effects_against_SARS-CoV-2_Rationalizing_the_Action_of_a_Potential_Multitarget_Antiviral_Agent/12782258
Professor Borody says his research has led him to a triple therapy of Ivermectin, zinc and an antibiotic - which are all TGA and FDA approved. The therapy comprises:
1. Ivermectin - TGA and FDA approved as an anti-parasitic therapy with an established safety profile since the 1970s. Known as the "Wonder Drug" from Japan. 2. Zinc 3. Doxycycline - TGA and FDA approved tetracycline antibiotic that fights bacterial infections, eg. acne or urinary tract infections, viral and malarial infections.
Professor Borody is involved in a Phase 2 study in the US to potentially develop the triple therapy as a single "blister pack" compliance product. He says, "Our study in the US is looking at developing the triple therapy as a single product which requires FDA approval, even though all 3 medications separately are already approved." US clinical trial notes: https://clinicaltrials.gov/ct2/show/NCT04482686?term=Ivermectin+borody
About the Centre for Digestive Diseases (CDD) The Sydney-based Centre for Digestive Diseases (CDD) provides patients with innovative therapies not available in the rest of the world. The Hospital features cutting-edge technologies enabling our specialists to provide world-class treatments. Visit https://centrefordigestivediseases.com.
Professor Borody is best known internationally for his work in gut and its mircobiome infections and re-purposing antimicrobial drugs for new diseases including the triple therapy cure for peptic ulcers. His discoveries prevented premature deaths in over 18,000 people and saved the Federal Government a reported $10 billion. [THEMA Report p.7]
Professor Borody developed a triple therapy for the treatment for Crohn's Disease, and has developed 4 FDA approved pharmaceuticals for the USA and international markets.
For interviews please contact: Kate Newton, Digital Mantra Group E: team@DMGPR.com; AU: +61 2 8218 2144 US: +1 415 951 3228; ASIA: +65 3159 3427
Source: Centre for Digestive Diseases (CDD) Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Four-strong TOYOTA GAZOO Racing squad to push for more Portugal success May 02, 2024 18:05 JST
| Spectacular Spa awaits TOYOTA GAZOO Racing May 02, 2024 17:46 JST
| Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore May 02, 2024 11:00 JST
| Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub Apr 30, 2024 19:08 JST
| New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg Apr 30, 2024 18:00 JST
| SPARX Group Establishes Space Frontiers Second Fund Apr 29, 2024 18:49 JST
| MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam" Apr 29, 2024 18:00 JST
| POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada Apr 29, 2024 14:25 JST
| Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada Apr 29, 2024 14:16 JST
| JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan Apr 26, 2024 10:00 JST
| Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024 Apr 25, 2024 18:21 JST
| MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park Apr 25, 2024 17:45 JST
| GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series Apr 25, 2024 16:50 JST
| Toyota Exhibiting at Beijing Motor Show 2024 Apr 25, 2024 16:25 JST
| Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada Apr 25, 2024 11:10 JST
| UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh Apr 25, 2024 09:00 JST
| Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
|
More Latest Release >>
|